TY-JUR T1 - 标准化较短的缩短方案与利福平或多药抗性结核结核病的个性化较长的方案JF - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003.01467-2019 VL - 55是 - 3SP - 1901467 Au - Abidi，Syed Au - Augion，Jay Au - Asao Neino，Mourtala Mohamed Au - Bang，Didi Au - Benedetti，Andrea Au - Brode，Sarah Au - Campbell，Jonathon R. Au - Casas，Esther C. Au- Conradie，Francesca Au - Dravniece，Gunta Au - Du Cros，Philipp Au - 法尔扎尼斯，Dennis Au - Jaramillo，Ernesto Au - Kuaban，Christopher Au - Lan，Zhiyi Au - Lange，Christoph Au - Li，Pei Zhi Au - Makhmudova，Mavluda Au - Maug，Aung Kya Jai Au - Menzies，Dick Au - Migliori，Giovanni Battista Au - Miller，Ann Au - Myrzaliev，Bakyt Au - Ndjeka，Norbert Au - Noeske，JürgenAu - 诺埃斯克，JürgenAu - Putevea，Nargiza Au - Piubello，Alberto Au- Schwoebel，ValérieAu - Sikhondze，Welille Au - Singla，Rupak Au - Souleymane，Mahamadou Bassirou Au - Trébucq，Arnaud Au - Van Deun，Armand Au - VIney，Kerri Au - Weyer，Karin Au - Zhang，Betty Jingxuan Au - Ahmad Khan，Faiz Y1 - 2020/03/01 UR - //www.qdcxjkg.com/content/55/3/1901467.abstract n2 -我们试图比较两个世界卫生组织（世卫组织）的效力 - 用于治疗利福平或多药物（RR / MDR）结核（TB）的治疗：9-12个月的标准方案（“较短的方案“）和个性化方案≥20个月（”更长的方案“）。我们从通过系统审查和公开呼叫进行数据审查的观察研究中收集了个别患者数据。我们包括符合较短方案的资格标准的患者：之前未用二线药物治疗，并用氟代喹啉和二线可注射剂 - 易感RR / MDR-TB治疗。我们使用倾向评分匹配，混合效应元回归，计算调整后的差异比例和调整后的风险差异（ARDS）进行失败或复发，治疗后12个月内的死亡和后续行动的死亡。3378中包括2625次（77.7％）从53项较长方案的研究中的较短方案和13个104（20.7％）个体中的九个研究的个体。治疗成功较短，方案较短，比较较长的方案（汇总比例80.0％而75.3％），由于前者的随访较少（ARD -0.15,95％CI -0.17-0.12）。 The risk difference for failure or relapse was slightly higher with the shorter regimen overall (aRD 0.02, 95% CI 0–0.05) and greater in magnitude with baseline resistance to pyrazinamide (aRD 0.12, 95% CI 0.07–0.16), prothionamide/ethionamide (aRD 0.07, 95% CI −0.01–0.16) or ethambutol (aRD 0.09, 95% CI 0.04–0.13).In patients meeting WHO criteria for its use, the standardised shorter regimen was associated with substantially less loss to follow-up during treatment compared with individualised longer regimens and with more failure or relapse in the presence of resistance to component medications. Our findings support the need to improve access to reliable drug susceptibility testing.Standardised shorter regimens for RR/MDR-TB had substantially lower risk of loss to follow-up than individualised longer regimens, but also higher risk of failure or relapse if there was resistance to component drugs http://bit.ly/2RQgXzq ER -